Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2003
03/20/2003WO2003002175A3 Enhanced systemic absorption of intradermally delivered substances
03/20/2003WO2003000195A3 Method and material for treating immune diseases
03/20/2003WO2002100845A8 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/20/2003WO2002100836A8 Compounds, compositions and methods for modulating beta-amyloid production
03/20/2003WO2002099075A3 Prmts as modifiers of the p53 pathway and methods of use
03/20/2003WO2002096354A3 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
03/20/2003WO2002092102A3 Treatment of conditions relating to hormone deficiencies by administration of progestins
03/20/2003WO2002087556A9 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002083113A3 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002069908A3 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
03/20/2003WO2002067951A3 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003WO2002062323A3 Use of mglur5 antagonists for the treatment of pruritic conditions
03/20/2003WO2002060393A3 Proteoglycan compositions for treatment of inflammatory conditions
03/20/2003WO2002053733A3 Regulation of human b7-h2 protein
03/20/2003WO2002053728A3 Gene disruption methodologies for drug target discovery
03/20/2003WO2002053171A3 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002032412A3 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
03/20/2003WO2002028408A3 Compositions and methods for the transport of biologically active agents across cellular barriers
03/20/2003WO2002022809A9 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002020718A9 Osteoclast-associated receptor
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2002004520A3 Transporters and ion channels
03/20/2003WO2002004490A3 Lipid metabolism molecules
03/20/2003WO2001087913A9 Method for treating retinal degeneration with purinergic receptor agonists
03/20/2003WO2001085219A3 Identification, diagnosis, and treatment of breast cancer
03/20/2003WO2001072341A3 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
03/20/2003US20030056240 Transgenic animal model for use in the treatment of diabetes
03/20/2003US20030055114 Methods and compositions for inhibiting the proliferation of prostate cancer cells
03/20/2003US20030055110 Retinoid compounds suited for antibacterial applications
03/20/2003US20030055107 Forms of pharmaceutically active agents and method for manufacture thereof
03/20/2003US20030055095 Administering to the patient a therapeutically effective amount of a compound that is an MEK inhibitor for inhibiting neutrophil migration
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055089 Endoparasiticidal and ectoparasiticidal agents
03/20/2003US20030055077 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055062 Heteroaryl urea neuropeptide Y Y5 receptor antagonists
03/20/2003US20030055049 For therapy of abnormal cell growth, such as cancer, in mammals
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055040 Cholinesterase inhibitors to treat disorders of attention
03/20/2003US20030055036 Method for treating a demyelinating condition
03/20/2003US20030055027 For therapy of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites
03/20/2003US20030055026 Formoterol/steroid bronchodilating compositions and methods of use thereof
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055014 Administering at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis
03/20/2003US20030055012 Prodrugs of COX-2 inhibitors
03/20/2003US20030055009 Administering a drug for stimulating hair growth, preventing hair loss, or retarding hair loss in a mammal
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030055004 GPE analogs and peptidominetics
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054993 For contraception in a mammal, for therapy of infertility
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054978 Arginine compound or conjugate thereof and one or more of a high molecular weight aliphatic alcohol and methyl donor cofactor and conjugates thereof
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054525 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R / (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
03/20/2003US20030054491 Peptide for use in the treatment of immunological, infectious and cancer disorders
03/20/2003US20030054490 Isolated human phosphatase proteins, nucleic acid molecules encoding phosphatase proteins and uses thereof
03/20/2003US20030054452 Lysolipid for use in controlling apoptosis and treating inflammatory and innumological disorders
03/20/2003US20030054446 Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
03/20/2003US20030054398 Isolated human aminotransferase proteins, nucleic acid molecules encoding aminotransferase proteins and uses thereof
03/20/2003US20030054365 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
03/20/2003US20030054341 Viral nucleotide sequences for use in diagnosis, prevention and treatment of viral diseases
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054030 Topical applying mixture of active material and lipid; side effect reduction
03/20/2003US20030054029 Iib/iiia antagonists co-administered with aspirin
03/20/2003US20030054026 Athletic patch
03/20/2003US20030054020 Method and composition for reducing sebum secretion in mammals
03/20/2003US20030054000 Anti-pathogen system and methods of use thereof
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
03/20/2003US20030053968 Compositions for the treatment of pigmentation disorders and methods for their manufacture
03/20/2003US20030053967 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light
03/20/2003US20030053957 Degradation-resistant glucocorticosteroid formulations
03/20/2003CA2460117A1 Expression profiling in the intact human heart
03/20/2003CA2460092A1 A method of diagnosis and treatment and agents useful for same
03/20/2003CA2460023A1 Method for treating coumarin-induced hemorrhage
03/20/2003CA2460022A1 Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
03/20/2003CA2459945A1 Methods of screening molecules that are used to prevent cardiovascular diseases
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459720A1 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths
03/20/2003CA2459713A1 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
03/20/2003CA2459560A1 Methods of kidney transplantation utilizing developing nephric tissue
03/20/2003CA2459533A1 Methods of treating pulmonary disease
03/20/2003CA2459457A1 Benzothiazepine derivatives for the treatment of hyperlipidemia
03/20/2003CA2459445A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003CA2459318A1 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003CA2459310A1 Method and composition for treating immune complex associated disorders
03/20/2003CA2459304A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
03/20/2003CA2458302A1 New assay for inhibitors of translocases
03/20/2003CA2457895A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003CA2457848A1 Use of 4-pyridylmethylphthalazines for cancer treatment
03/20/2003CA2455990A1 Methods for diagnosing and treating diseases and conditions associated with protein kinase c.lambda.
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/19/2003EP1293562A1 Fungal glyoxal oxidases
1 ... 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 ... 1151